Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.
Message: TPL, Moore and Dr. Nick
I hope that Dr. Nick is giving us the same good advice. This is what we should be doing with our proceeds from licensing.
The TPL Group currently employs more than 100 experienced technologists with nearly half of them holding MS and/or PhD degrees. The technologists are engaged in developing advanced semiconductor products, some of which are currently shipping.
Proceeds from MMP licensing transactions are being used by Mr. Moore and TPL to jointly develop revolutionary new microprocessor technologies and microprocessor devices, some of which have been introduced by TPL and heralded by microprocessor industry analysts and trade media. These new technologies are the subject of a variety of new patent applications, which, if the patent system remains reliable and predictable, should support yet another round of innovation by Mr. Moore and TPL.http://www.tplgroup.net/tplbg.pdf
Dr. Nick Tredennick is an advisor and investor in numerous pre-IPO startups and is a member of technical advisory board for the TPL Group as well as other high-tech companies including OpenReach, Impinj, QuickSilver Technology, QuickFlex, and the Venture X Group. He serves as editor of the Gilder Technology Report and is on the editorial advisory board for several technical publications including IEEE Spectrum, Microprocessors and Microsystems, Embedded Developers Journal, and Microprocessor Report. Dr. Tredennick was named a Fellow of the IEEE for his contributions to microprocessor design. He has over 30 years' experience in computer and microprocessor design, holds nine patents, and has more than fifty technical publications, including a textbook on microprocessor design (Microprocessor Logic Design).
4 Recommendations
Loading...
Loading...
New Message
Please
login
to post a reply